Gold bars to be exempt from tariffs, White House clarifies
LONDON - AstraZeneca PLC (LSE/STO/Nasdaq: LON:AZN), the UK-based biopharmaceutical company, has published its Annual Report and Form 20-F Information for the year 2024. The report, which details the company's performance and ongoing strategies, will be available for inspection at the National Storage Mechanism and can also be accessed on AstraZeneca (NASDAQ:AZN)'s website.
The company has announced that the Annual Report will be distributed to shareholders soon and that the Annual General Meeting (AGM) is scheduled for April 11, 2025. The Notice of AGM and Shareholders' Circular will be published and sent to shareholders in due course.
In compliance with the Disclosure and Transparency Rules, the Annual Report includes essential regulated information such as the principal risks and uncertainties facing the company, the Directors' responsibility statement concerning the Financial Statements and Directors' Report, and a statement on related party transactions.
AstraZeneca is known for its focus on the discovery, development, and commercialization of prescription medicines across various therapeutic areas, including Oncology, Rare Diseases, and BioPharmaceuticals, which covers Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. The company's products are available in over 125 countries and are used by millions of patients worldwide.
The information provided in this article is based on a press release statement from AstraZeneca PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.